In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
The in-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid was determined against 1499 Gram-negative and 279 Gram-positive isolates from different clinical institutions in the Federal Republic of Germany. 90% of all Enterobacteriaceae were inhibited by 0.5 mg/l. Glucose non-fermenting Gram-negative rods and staphylococci were less sensitive to all 4-quinolones. All Gram-negative strains selected for resistance to nalidixic acid were significantly less sensitive to the new generation of 4-quinolones tested.
D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000382:microbiology; D015365:Enoxacin; D006801:Humans; D008826:Microbial Sensitivity Tests; D009268:Nalidixic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology*; D009287:Naphthyridines / Q000494:pharmacology*; D009643:Norfloxacin; D015242:Ofloxacin; D010078:Oxazines / Q000494:pharmacology*
D009287:Naphthyridines; D010078:Oxazines; D015365:Enoxacin; D009268:Nalidixic Acid; D015242:Ofloxacin; D009643:Norfloxacin